FEB 2 9 2008 W

th (609

Approved for use through 02/29/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number **Application Number** 10/574 862 TRANSMITTAL Filing Date April 6, 2006 First Named Inventor **FORM** Pugia, et al Art Unit 1609 **Examiner Name** Sharon Wen (to be used for all correspondence after initial filing) Attorney Docket Number 017191.0049 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Extension of Time Request Terminal Disclaimer below): Acknowledgement postcard Request for Refund Express Abandonment Request CD, Number of CD(s)_ Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Kelley Drye & Warren LLP Signature n. mella Printed name Harold N. Wells Date Reg. No. February 27, 2008 26.044 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Heide Eberhart

Typed or printed name

Date

2/27/08





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re U.S. Patent Application) Customer No.: 47670
Applicant:	Michael J. Pugia, et al.)
Serial No.:	10/574,862) I hereby certify that this correspondence is) being deposited with the United Postal Service as First Class Mail in an envelope addressed to: Mail Stop AMENDMENT, Commissioner of Patents, P. O. Box 1450, Alexandria, VA, 22313-1450, on February 27, 2008) Characteristic Commissioner of Patents, P. O. Box 1450, Separature Characteristic Commissioner of Patents, P. O. Box 1450, Signature
Filed:	April 6, 2006	
For:	Monoclonal Antibodies for Detection of Urinary Trypsin Inhibitors	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§1.97 and 1.98

Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Commissioner:

In compliance with the duty of disclosure under 37 C.F.R. §1.56, it is respectfully requested that this Information Disclosure Statement be entered and the reference(s) listed on attached Form PTO-1449 be considered by the Examiner and made of record. Each of the references is a publication in which the first named inventor is an author and published in 2006 or 2007.

In accordance with 37 C.F.R. § 1.98(a)(2)(ii), copies of the listed references are enclosed. In accordance with 37 C.F.R. §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information disclosed is, or is considered to be, prior art with respect to the present application or material to patentability as defined in 37 C.F.R. §§ 1.56.

The present Information Disclosure Statement is being filed before the mailing of a First Office Action after filing of an RCE in the subject application and hence is believed to be timely in accordance with 37 C.F.R. § 1.97(b)(4). Accordingly, no fees are believed to be due in connection with the filing of this Information Disclosure Statement. However, should any fees be deemed necessary (except payment of the issue fee), the Commissioner is authorized to charge any deficiency or to credit any overpayment to Kelley Drye & Warren LLP Account No. 11-0404/017191.0049.

Respectfully submitted,

Date

2/27/08

Harold N. Wells Reg. No. 26,044

Kelley Drye & Warren LLP

333 West Wacker Drive, Suite 2600

Chicago, IL 60606

(312) 857-2336

(312) 857-7095 (Fax)

Attorneys for Applicant